PharmaTher Holdings Ltd (QB) (PHRRF)

Whatever the deal he has to bring in revenue and grow the company, I am pretty that is on his agenda and to benefit out of the company financially.
Overall things are looking good fwd and poised for the $1 run imo. I have a good feel on this stock and will meet the targets, old timers need to jump back on this boat and enjoy the ride. Lot of trading last 3 days lot of new eyes and new positions being added here.

We need a good deal on the patch,hopefully the CEO does a better deal than last time.

Soon they will report revenues big run ahead

$1 to $2 on the horizon.Tip Ranks will update shortly

Huge volume after a long time.
Catalysts start showing up some value I guess. Could be huge here on.

Maybe something is in the works,Maybe an International deal.GLTA.

PPS making nice move up today on decent volume 
GLTA shareholders 

Looks like the market responded to the recent PRs. Major drop in PPS and MC. NG
Perhaps the CEO should consider buying some more shares? 
GLTA shareholders 

I agree,I think its the best way to move forward with their pipeline.

Here's a very recent AI analysis of Pharmather's likely sell of it's Ketamine ANDA and the likely involvement of Caplin Steriles. I believe it makes for a very optimistic outlook for Pharmather.

"Strategic Analysis of the Ketamine Hydrochloride Injection ANDA Divestiture: Implications for PharmaTher Holdings Ltd. and the AcquirerExecutive Summary: The Strategic Pivot and Asset MonetizationThe sale of Abbreviated New Drug Application (ANDA #217858) for Ketamine Hydrochloride Injection USP represents a definitive strategic inflection point for PharmaTher Holdings Ltd. The transaction, announced in October 2025, successfully transitions the company away from the volatile, low-margin dynamics of generic pharmaceutical production toward a focused specialization in high-value, proprietary ketamine therapeutics utilizing the regulatory efficiency of the 505(b)(2) pathway.Financially, the divestiture provides immediate, non-dilutive funding through a confidential upfront cash payment, positioning PharmaTher to fully fund its initial clinical goals through its regulatory timelines. Further compounding the value, the agreement includes eligibility for milestone payments contingent on cumulative sales thresholds, coupled with an ongoing profit-sharing mechanism that extends for seven years following the first commercial launch. The total potential consideration from this contingent structure exceeds US$25 million.The profile of the undisclosed buyer—a global pharmaceutical company specializing in sterile injectables with over 40 approved ANDAs in the U.S. and FDA-approved manufacturing capabilities —aligns strongly with Caplin Point Laboratories Ltd., specifically through its subsidiary, Caplin Steriles Ltd. Caplin Steriles is a niche, FDA-approved sterile product manufacturer demonstrating an aggressive expansion strategy into the U.S. regulated market. The sale structure is notable as it guarantees PharmaTher long-term exposure to the generic market upside while allowing the company to retain crucial intellectual property (IP). Crucially, the sale allows PharmaTher to leverage the foundational Chemistry, Manufacturing, and Controls (CMC) package, which was already reviewed and accepted by the FDA for the ANDA, thereby accelerating development and potentially saving substantial time and cost for its future proprietary New Drug Applications (NDAs).Section 1: Contextualizing the Ketamine Landscape and Market Dynamics1.1 The Dual Market of Ketamine: Generic Anesthesia vs. Proprietary TherapeuticsKetamine operates within a bifurcated pharmaceutical landscape. Originally approved in 1970 as a dissociative anesthetic , generic injectable ketamine (the focus of the sold ANDA) remains essential in hospital and surgical settings. The commercial environment for generic injectable ketamine is characterized by high volume but faces intense commodity pricing pressure typical of multi-source injectables.In contrast, the market for proprietary ketamine derivatives and formulations is focused on novel indications. Subanesthetic doses of ketamine have emerged as rapid and powerful agents for treatment-resistant depression and chronic pain, fueling widespread off-label use since the 2010s. The regulatory approval of esketamine (the S-enantiomer) in 2019 provided regulatory validation for ketamine's use in psychiatric disorders. PharmaTher’s strategic shift targets this higher-margin sector, utilizing the existing drug’s safety profile to pursue novel indications like Complex Regional Pain Syndrome (CRPS) and Parkinson’s disease via advanced delivery systems like the microneedle patch.1.2 Regulatory Frameworks Governing Ketamine Development (ANDA vs. 505(b)(2))The type of regulatory pathway dictates the commercial value and development cost of a drug. The Abbreviated New Drug Application (ANDA) pathway, under which the sold asset was filed, is designed for generic equivalents. It requires demonstrating bioequivalence to a Reference Listed Drug (RLD) and is aimed at providing cost-effective, high-volume supply.PharmaTher’s new focus is the 505(b)(2) pathway. This pathway is designed for new drug applications that rely, in part, on the FDA’s findings of safety and efficacy for a previously approved drug (such as generic IV ketamine) but require new clinical or non-clinical data for a modification, such as a new indication, a novel formulation, or a new delivery system. This strategy is foundational to PharmaTher’s pivot because leveraging existing FDA-approved data significantly reduces the time and expense associated with a full New Drug Application (NDA) requiring Phase 1, 2, and 3 trials for a completely novel compound.1.3 Macroeconomic Analysis of the U.S. Generic Sterile Injectables MarketThe decision to divest the ANDA is highly correlated with the challenging economics of the U.S. generic sterile injectables market. This sector has historically been plagued by persistent drug shortages, which carry substantial public health costs. A critical factor contributing to these shortages is the inherently low profitability of generic injectables. Data suggests that in aggregate, the market barely achieves positive returns, with 70% of launched generic injectable products failing to achieve a positive Return on Investment (ROI) by the third year following launch. This environment is significantly less profitable and more volatile than the market for generic oral drugs.This low-ROI, high-risk operational environment provides strong economic justification for PharmaTher’s strategy. As a specialty pharmaceutical company that lacks the large-scale distribution and competitive manufacturing infrastructure of a generic giant, it is strategically rational to monetize the regulatory groundwork (the ANDA) for non-dilutive capital rather than undertake the operational complexity and financial volatility of competing in the commodity market. The sale, announced near the anticipated FDA approval date of August 9, 2025 , allows PharmaTher to avoid the intense pricing competition and required commercial build-out that would commence immediately upon regulatory approval, thus guaranteeing capital proceeds upfront while retaining upside through the profit-sharing mechanism. Furthermore, the company’s strategic shift to focus on high-margin, rare disease treatments, such as CRPS and Parkinson's , positions it favorably in alignment with federal initiatives emphasizing non-opioid pain relief (CNPV National Priority Initiative) and mental health treatments.Section 2: The Acquirer Profile: Strategic Necessity in Generic Injectables2.1 Deep Dive into the Buyer Profile: Credentials and Focus AreaThe buyer of ANDA #217858 is described as a "well-established global pharmaceutical company specializing in sterile injectables and complex generics". Specific details provided include that the company possesses FDA-approved manufacturing capabilities and maintains a substantial portfolio of "over 40 approved ANDAs in the U.S.". The buyer explicitly requested confidentiality regarding its identity, citing "strategic business reasons, including competitive positioning in the U.S. ketamine and sterile injectable generics market". This request underscores the competitive advantage gained by securing control of this injectable product supply.2.2 Caplin Steriles Ltd.: Capabilities, R&D Focus, and US FDA Track RecordCaplin Steriles Ltd., a subsidiary of Caplin Point Laboratories Ltd., demonstrates a corporate profile that perfectly matches the buyer's description. The company is FDA- and EU-GMP-approved, focused exclusively on developing and manufacturing high-quality Injectables and Ophthalmic products for regulated international markets, including the US.Caplin Steriles maintains a significant US presence, having filed 19 Abbreviated New Drug Applications (ANDAs) and holding 11 FDA approvals as of early 2021. The company has outlined an aggressive pipeline targeting 35+ additional ANDAs for future filing. Recent successful FDA approvals for products such as Haloperidol Decanoate Injection and Ephedrine Sulfate Injection underscore its continuous, aggressive expansion into the U.S. sterile injectable market. Furthermore, Caplin Steriles explicitly invests in advanced technologies and capacities, including lyophilized vials, pre-mixed bags, long-acting sterile suspensions, and importantly, Prefilled Syringes (PFS). The aggregate number of ANDAs approved by Caplin Steriles and its parent organization aligns closely with the buyer’s stated profile of 40+ approved ANDAs.2.3 Analysis of Fit: Why Caplin Steriles is the Logical Acquirer of ANDA #217858The congruence between the stated requirements of the undisclosed buyer and the documented capabilities of Caplin Steriles suggests that the Indian-based specialist is the highly probable acquirer of ANDA #217858.First, the core business alignment is precise: Caplin Steriles' dedicated focus is sterile injectables, which matches the buyer’s stated expertise. Second, securing a generic ketamine ANDA provides the buyer with control over a critical supply chain product that is utilized across multiple segments, from anesthesia to increasingly popular off-label infusions for pain and psychiatric disorders. For an ambitious market entrant like Caplin Steriles, this acquisition represents immediate regulatory validation and substantial volume potential in a key commodity therapeutic area.The buyer’s insistence on confidentiality for competitive reasons highlights the tactical nature of the purchase. Considering the documented volatility and prevalence of drug shortages in the U.S. generic injectable market , securing an FDA-approvable ANDA for ketamine provides a significant, immediate competitive advantage in stabilizing supply. By preventing competitors from anticipating their market entry or supply capacity until the commercial launch, the buyer maximizes its market impact and optimizes pricing power, particularly during the initial years of the profit-sharing agreement.Moreover, Caplin Steriles’ stated research and development interests, which include Novel Drug Delivery Systems (NDDS) such as Prefilled Syringes , indicate a sophisticated understanding of the evolving market needs for user-friendly, high-quality sterile products. This strategic focus mirrors PharmaTher's retention of IP rights for advanced delivery mechanisms like the microneedle patch. This shared appreciation for novel delivery technology could signal the potential for a deeper, long-term strategic relationship centered on co-development or licensing of advanced ketamine delivery platforms, extending beyond the immediate generic ANDA transaction.Section 3: Dissecting the Asset Purchase Agreement (ANDA #217858)3.1 Transaction Overview and TimelineThe definitive Asset Purchase Agreement for ANDA #217858, covering Ketamine Hydrochloride Injection USP, was announced on October 1, 2025. This transaction occurred shortly after the FDA had set an approval goal date of August 9, 2025, for the product. The proximity of the sale to the regulatory decision maximized the asset’s maturity, ensuring the buyer acquired a product nearly ready for commercialization, capable of leveraging their "established track record" and existing infrastructure in the sterile injectable market.3.2 Financial Structure: Upfront Payment, Milestones, and the 7-Year Profit-Sharing MechanismThe financial terms of the transaction were structured to provide PharmaTher with both immediate and long-term participation in the generic ketamine market success, mitigating the risk of undervaluing the asset.The core financial components include: * Upfront Cash Payment: A confidential cash payment was received by PharmaTher upon closing, providing essential immediate non-dilutive capital. * Contingent Milestone Payments: PharmaTher is eligible to receive milestone payments based on achieving specific cumulative sales thresholds. * Profit-Sharing Arrangement: A sustained revenue stream is structured through an ongoing profit-sharing arrangement spanning seven years following the first commercial sale. * Total Potential Consideration: The cumulative value contemplated by the agreement, contingent upon commercial performance, is stated to exceed US$25 million.3.3 Valuation Assessment: Modeling the Contingent ValueThe seven-year profit-sharing term, extending potentially through 2032 or 2033, represents a critical element of the agreement. While generic markets rapidly saturate and margins erode over time, the highest profitability and market capture typically occur in the first few years after launch. The extended profit-sharing mechanism suggests a shared conviction by both PharmaTher and the buyer in the durable, sustained commercial viability of generic injectable ketamine. This confidence is likely driven by the rapidly growing off-label use of IV ketamine infusions in psychiatric clinics for mental health disorders , which ensures robust and expanding demand volume for the injectable formulation well beyond the initial product launch phase.3.4 Regulatory Status Post-Sale: Retention of Proprietary Developmental RightsA crucial aspect of the Asset Purchase Agreement is the explicit reservation of intellectual property rights by PharmaTher. The company retained full rights to research, develop, manufacture, and commercialize all other strengths, dosage forms, or formulations of ketamine for any indication globally, including the US. The only restriction is developing the exact same generic product approved under ANDA #217858. This retention covers all proprietary programs, including those for Complex Regional Pain Syndrome (CRPS), Parkinson’s disease, ALS, and the novel delivery systems such as the microneedle patch and wearable pump.This agreement provides a secondary, non-monetary benefit: PharmaTher can leverage the Chemistry, Manufacturing, and Controls (CMC) package that was validated and accepted by the FDA for the generic ANDA. The CMC section is typically the most expensive and time-consuming part of a drug application. By relying on this established regulatory foundation, PharmaTher substantially de-risks and accelerates the timeline for its future, differentiated 505(b)(2) New Drug Applications, ensuring its focus remains on innovative, non-generic products.Key Terms of the Ketamine ANDA #217858 Asset Purchase Agreement| Transaction Component | Details | Significance for PharmaTher ||---|---|---|| Asset Sold | ANDA #217858 for Ketamine Hydrochloride Injection USP  | Offloads commercial risk for a low-margin commodity product  || Upfront Payment | Confidential Cash Payment | Immediate, guaranteed non-dilutive capital  || Contingent Consideration | Milestone Payments based on cumulative sales thresholds | Alignment of seller/buyer long-term success  || Profit Sharing Period | 7 Years Following First Commercial Sale | Exposure to early-stage, high-volume generic sales  || Total Potential Value | Exceeds US$25 Million | Funds pivotal clinical trials (CRPS, Parkinson's)  |Section 4: PharmaTher's Strategic Divergence: The Shift to 505(b)(2)4.1 Rationale for Divestiture: Monetization as Non-Dilutive CapitalThe primary driver for the ANDA sale was to secure a substantial source of non-dilutive funding, thereby providing capital to advance high-risk, high-reward proprietary research without immediate reliance on restrictive equity or debt financing. The company's CEO, Fabio Chianelli, affirmed that the transaction "validates the significant value embedded in our ketamine assets" and, more importantly, facilitates the advancement of "our proprietary next-generation therapies". This move is a textbook pharmaceutical strategy: trading the certainty of a commodity market's regulatory success for the speculative, yet vastly higher, returns associated with differentiated therapeutic innovations.4.2 Leveraging the CMC Package for Expedited NDA FilingsPharmaTher’s future strategic success hinges on the 505(b)(2) regulatory pathway. By leveraging the validated CMC package from the generic ANDA , the company expects to save significant time and development costs, as the regulatory burden is shifted from demonstrating foundational safety and manufacturing quality to proving the efficacy of a modification (e.g., new indication or new delivery method). This allows PharmaTher to focus exclusively on developing products that are "differentiated and non-generic".4.3 Focus on High-Value, Near-Rare Indications: Detailed Review of CRPS and Parkinson's ProgramsPharmaTher has specifically directed its resources toward therapeutic applications in rare and near-rare disorders , a segment that typically affords faster regulatory pathways, premium pricing, and market exclusivity upon approval—all factors designed to maximize ROI far exceeding generic market profitability. * Complex Regional Pain Syndrome (CRPS): CRPS is a debilitating, often treatment-resistant chronic pain condition. PharmaTher is prioritizing meetings with the U.S. FDA to define an expedited clinical and regulatory path for ketamine in CRPS. Targeting this condition aligns the company with high-unmet-need areas, which often qualify for specific designations like Orphan Drug Status. * Parkinson's Disease: The company is also seeking FDA agreement on the Phase 3 study design for ketamine in treating Parkinson's disease. This application addresses movement disorders, further demonstrating a commitment to high-impact neurological conditions, setting its focus apart from the common use of ketamine in psychiatry.Successful navigation of the FDA guidance process for these programs is critical. Favorable outcomes regarding Phase 3 study design significantly de-risk the assets, positioning them as "attractive candidates for potential partnerships with larger pharmaceutical companies". The ultimate attractiveness of these assets, both for investors and major pharmaceutical partners, is highly dependent on securing regulatory endorsement of streamlined clinical trial designs.Proprietary Ketamine Pipeline and Delivery Differentiation| Product/Indication | Target Condition | Delivery System | Regulatory Path/Stage | Competitive Advantage ||---|---|---|---|---|| Ketamine for CRPS | Chronic Regional Pain Syndrome | Undetermined (Likely patch/pump later) | Seeking FDA guidance for Phase 3  | Addresses high unmet need in chronic pain (Non-Opioid)  || Ketamine for Parkinson's | Movement Disorder | Undetermined | Seeking FDA agreement on Phase 3 design  | Novel therapeutic application leveraging 505(b)(2) efficiency || Ketamine Patch | Chronic Pain/Neuropsychiatric Use | Microneedle Patch | NDA (505(b)(2) leveraging IV data)  | Potential for reduced pain, self-administration, enhanced compliance  |Section 5: Next-Generation Delivery Systems and Commercialization Strategy5.1 Technology Overview: Ketamine Microneedle Patch and Wearable Pump ProgramsPharmaTher’s proprietary pipeline is centered on innovation in drug delivery. The company is actively developing the Ketamine Patch and KetaVault, a wearable pump system. These advanced systems are pivotal to the strategy because they fundamentally change the mode of administration, transitioning ketamine from a heavily monitored clinical infusion (intravenous use)  to potentially self-administered, controlled delivery via transdermal or subcutaneous routes.5.2 Drug Delivery Innovation vs. Conventional Injection: Advantages in Compliance and PharmacokineticsThe utilization of advanced delivery systems provides a significant competitive advantage over conventional generic injectable formulations. Microneedle technology, in particular, has been viewed positively by both the public and healthcare professionals. Perceived benefits include reduced pain, less tissue damage, a lower risk of infection, and the critical potential for self-administration.Current standard-of-care IV ketamine infusion for depression or chronic pain mandates a lengthy period of post-treatment monitoring due to potential dissociative adverse effects. This clinical overhead significantly limits scalability and incurs high costs. If the microneedle patch can deliver effective therapeutic plasma concentrations (e.g., 70 to 200 \text{ng}/\text{mL} for antidepressant effects) while mitigating these side effects, it could obtain approval for at-home use. Such an approval would dramatically alter the cost structure and convenience profile of ketamine treatment, opening access to the massive at-home chronic pain and neurological markets. This differentiation justifies the premium pricing inherent in the 505(b)(2) development model.5.3 Global Partnership Strategy: Identifying Targets for International Expansion and Clinical FundingTo sustain the capital-intensive clinical development required for the 505(b)(2) pipeline, PharmaTher is actively pursuing international partnerships. The goal is to secure "additional non-dilutive funding" and accelerate the development and commercialization timelines. The company is strategically preparing for international regulatory submissions in key regulated markets, including Europe, the United Kingdom, Canada, Japan, and the Asia-Pacific (APAC) regions, with submissions expected to commence in the second half of 2025.The pursuit of these partnerships is a crucial step toward validation. Specialty pharmaceutical companies focused on novel delivery systems often lack the comprehensive global sales and distribution networks necessary for mass market launch. Therefore, securing a robust late-stage licensing agreement or acquisition by a major pharmaceutical partner capable of executing global commercialization  will be the ultimate determinant of the commercial success and valuation multiplication of PharmaTher's assets.Section 6: Competitive Positioning and Forward-Looking Recommendations6.1 SWOT Analysis of the Acquirer in the Generic Ketamine Market (Assuming Caplin Steriles)Assuming Caplin Steriles Ltd. is the undisclosed buyer, its strategic positioning in the generic ketamine market can be assessed as follows:| Factor | Description ||---|---|| Strengths | Established, FDA-approved sterile manufacturing capability; substantial existing U.S. ANDA portfolio (40+ approvals attributed to the Buyer group); financial stability provided by the parent company. || Weaknesses | Exposure to intense competitive pricing pressure inherent in the generic injectable market; risk of over-reliance on a commodity product with notoriously thin margins. || Opportunities | Ability to capitalize on chronic market shortages in the US; leveraging the sustained, increasing demand for ketamine driven by its growing off-label use in psychiatric and pain management infusions. || Threats | Market saturation from competitors; volatility in raw material pricing; regulatory restrictions or increased controls placed on off-label ketamine use. |6.2 Strategic Recommendations for PharmaTher regarding Clinical Trial Design and Partnership NegotiationThe success of PharmaTher’s strategic pivot depends on disciplined execution and maximizing the distinctiveness of its assets. * Maximize Clinical Differentiation: The Phase 3 study designs for CRPS and Parkinson's programs must utilize endpoints that demonstrably prove superior clinical outcomes, enhanced safety, or improved tolerability compared to conventional IV ketamine. This is particularly vital if the studies integrate the proprietary microneedle patch or wearable pump delivery systems, which could show improved pharmacokinetics or patient compliance. * Prioritize Non-Dilutive Financing: In partnership negotiations, the company should prioritize securing global partners who offer substantial upfront development funding and co-development rights. This strategy is necessary to finance the multi-year clinical runway typically required for 505(b)(2) product approval, preserving shareholder equity. * Validate CMC Leverage: PharmaTher must aggressively utilize the previously FDA-reviewed CMC package from ANDA #217858 in its current 505(b)(2) submissions to realize the expected time and cost savings.6.3 Risk Assessment: Regulatory Hurdles and Market Saturation in the Broader Ketamine Therapeutic SpaceWhile the 505(b)(2) pathway is generally expedited, it is not without significant risk. If the FDA determines that the new indications (CRPS, Parkinson's) or the novel delivery systems introduce unforeseen safety concerns or require extensive efficacy data that cannot be supported by the RLD documentation, the FDA may demand extensive new clinical trials equivalent to a full NDA. This outcome would significantly diminish the anticipated timeline savings and increase capital requirements.Additionally, the psychiatric ketamine market is highly dynamic, with numerous companies pursuing novel compounds or alternate delivery methods for depression and mood disorders. PharmaTher’s future valuation rests on its ability to maintain focus on differentiated, rare, and near-rare indications, which helps minimize direct competition from the rapidly evolving broader ketamine therapeutic space.ConclusionsThe divestiture of the Ketamine Hydrochloride Injection ANDA is analyzed as a highly sophisticated and rational strategic maneuver rather than a simple asset sale. It successfully executes a pivot for PharmaTher, exchanging a low-margin commodity asset for substantial non-dilutive capital and regulatory foundation (CMC data) to fund its high-growth, high-value proprietary pipeline. The financial structure—featuring an upfront payment, milestones, and a seven-year profit share—ensures PharmaTher participates in the generic market's success while offloading its operational risk.The highly probable acquirer, Caplin Steriles Ltd., secures a critical, high-demand injectable product. Importantly, the sale creates a symbiotic commercial relationship: as PharmaTher advances proprietary ketamine applications for high-profile conditions like CRPS and Parkinson's, it inherently broadens the legitimacy and medical adoption of ketamine, which indirectly drives market demand for the generic injectable product now owned by the acquirer. PharmaTher’s ultimate valuation depends now on securing positive FDA guidance for its Phase 3 programs  and successfully demonstrating the superiority and commercial feasibility of its next-generation delivery systems, such as the microneedle patch, which promises to transform the accessibility and cost-effectiveness of ketamine therapy."

thank you

Why don't you look up the form 10 filings for the CSE Pharmather.

"Total aggregate consideration in Canadian dollars: Upfront USD$150,00 (approx. CA$200,000), possible Sales milestone of up to USD $25,000,000 (approx.CA$35,000,000), calculated on the basis of estimated potential sales that may be achieved during the term of the agreement, ongoing Profit-sharing with no cap for term."

There is no mention of them determining the royalties later. The amount has already been determined. What they don't know, is how large the sales will be. I'm sure they could have received more upfront, with less on profit sharing, but he likely took higher royalties with less upfront.

Caplin (India Based) is a 155 billion dollar company with a subsidiary Caplin Steriles here in the US. They appear to be very aggressive, and they also have outreach to many countries worldwide. Pharmather's agreement is for the US only, I'm sure other territorial deals will be forthcoming, as more foreign regulatory approvals occur.

There is a rumor that the company that we partnered with is caplin sterile injectables and the deal was not good.They gave Fabio 200 thousand up front and will decide how much the royalties will be later.I don't know if its true but does not sound like a good deal.

I agree 100 percent with you,the problem was that the 1st PR was not done correctly and the update was what should have been put out first.The 1st PR is why it tanked.Crucial details was not on the 1st PR like the partner has commercial infrastructure to compete with existing ketamine competitors in the USA market and other markets around the world that they are working on with other companies and other details.

He absolutely made the right decision. How many small pharma companies on the OTC, can or will claim a cash stream of 25 million, over the next seven years? They were looking at tons of dilution and likely years of large net losses, just to perhaps someday becoming profitable.

I don't think people realize the expense of going it alone, to manufacture and market a drug.

This will allow them the ability to focus on overseas approvals, the new ANDAs, and the patch. While offsetting those costs and expenses with the proceeds from this deal.

As soon as more details emerge about the partner and deal, we should recover, and then some.

Fabio made the right moves and he explains why in his update this morning. There won't be dilution and the partner will do the manufacturing , sales , etc. Fabio also said the partner is connected so they could actually sell it , and connections is big in business. The partners sales team already have customers so sales won't be a problem.

Adding !!!

$PHRRF 1 Month chart https://schrts.co/pJjIGcmz
weekly - https://schrts.co/NBTyHJWU

$PHRRF Trending

Thank you for the response..

We need some sustainable traction. I’ve held for as long as I’ve held so waiting another 12 to 24 months in my opinion will be well worth it.

We need some sustainable traction. I’ve held for as long as I’ve held so waiting another 12 to 24 months in my opinion will be well worth it.

I dumped all of mine today. I just can't see this scam continuing for much longer. It's really a joke.

We are at the beginning here,there are many paths forward now that we have FDA approval.Maybe a merger would be good here.The CEO just needs to make things happen.GLTA

The news today was critical for this company, but it was also widely expected. Over the weekend I surveyed other message boards, and the messages were very bullish. Many talked about how far the stock would run up today, if the FDA approved our application. Some of the estimates being very, shall I say, "optimistic." My takeaway and thoughts were, that much of the float, was in the hands of sellers, looking to cash in, or long term holders, wanting to see how this story ends. Also, most of those interested in and knowledgeable about the stock, already had their shares and weren't talking about buying more.

The approval was a catalyst in itself, but it also unlocks several other pathways, which are not priced into the stock. Signing supplier contracts (revenue stream), partnerships, and filing new applications with the FDA for their other ketamine initiatives, are now things we can look forward to.

Finally, this is an unknown small company. News like this takes time to percolate with new investors, especially those who are risking large amounts of capital. My opinion is, at least for myself is to remain patient, and let them make the moves they need to make. After all, they achieved an FDA approval, and this is something many others have thus far, failed to accomplish.

I can't believe with this Great News that this stock has not taken off! This is a game changer for this very small company, probably on some one's radar by now. FDA approval is huge for them. Let's see what the next 6 to 12 months do for appreciation of this stock price. Less than 100 million shares outstanding factor in the warrants and stock purchase agreements will probably take the outstanding to 110 million, not bad, multiply share price, company could be snatched up soon.

https://www.globenewswire.com/news-release/2025/08/11/3130994/0/en/PharmaTher-Announces-FDA-Approval-of-Ketamine-KETARx.html

appreciate your opinions, what do you see next?

Congratulations everyone, we got our FDA approval for Ketarx!!! I've been waiting and holding for 2 years.

$PHRRF Ketamine FDA approved! August 2025
https://pharmather.com/uploads/1/2/5/8/125844350/deck_-_phrm_-_1020201.pdf

I'm just sitting here thinking through the Friday halt, and thought I'd share my thoughts.

Why would a CEO initiate a halt on Friday, with a goal date the next day? We can assume he received a decision from FDA. If that's the case, why the halt? Many believe it is because he didn't want news to leak out. This doesn't add up, because this is a small group of people, and not a huge corporation, with hundreds of executives to be concerned with about spilling the beans. In fact, it is likely that he himself, was the only one privy to the information. It's possible this was done to avoid perception of insider trading, but as stated earlier, the insider class is small.

If the news was bad, (delay or denial) why halt the stock? He could have allowed the stock to trade out, and released the news after the market close, which he didn't. On the other hand, if the news is good, what better way to send a message or flare to the market and investors to stay tuned. In other words, why halt the stock, drawing attention to it, and then release disappointing news? That would make no sense.

Some might argue the CEO can't initiate a halt like that, but on the TSX he can, and the OTC has to follow suit. The authorities and exchange wouldn't be privy to a news event, and they don't halt automatically because of an upcoming goal date.

In the past CRL's and delays didn't cause a halt. In my opinion, they have their approval, and the CEO is taking his time writing and preparing his PR, and how and where it will be released.

I don't usually like to post information, that might cause someone to buy and lose money. However, this is safe situation, because we will all find out together.

Hey, it's only my thoughts and opinion.

U1 trading halt 

$PHRRF Loading zone. https://schrts.co/heRzkrCB

$PHRRF Overall average - 100% Buy
Overall Average Signal calculated from all 13 indicators.
https://www.barchart.com/stocks/quotes/PHRRF/opinion

$PHRRF Odds of FDA approval are very good.
Per ChatGPT 4:
“…the odds of FDA approving Ketarx on or before that date are high—likely in the 80–90% range.”
Per Grok 4:
“…the probability of approval on or before August 9, 2025, is approximately 85%.”

Forgot about this one

Yeah, and on pretty decent volume. People want this right now. It's been a controlled and steady climb, that's what I like seeing, (solid accumulation).

$PHRRF increasing nicely each of the last 8 trading days. Sweet!

Right back at you!!!

I wish you good fortune!

Oh yeah, you're not alone:) I'm just waiting patiently, like I have for the last couple years. We could very well see some fireworks soon. Many things going on with this company, if they get FDA approval.

Well, I'm here, and I bought in on 6/13 @ .17, and I am very exited. Is there anyone else out there? I think the potential for this stock speaks for itself. On August 8, we will skyrocket.

PharmaTher Holdings Ltd. .80 cent warrants, what the PPS now?
Notes to Condensed Interim Consolidated Financial Statements
November 30, 2024
(Expressed in Canadian Dollars)
(Unaudited)
6. Warrants and broker warrants
The Company issued warrants and broker warrants to acquire common shares as follows:
Number of Weighted Average
Warrants Exercise Price ($)
Balance, May 31, 2023, November 30, 2023, May 31, 2024
and November 30, 2024 16,875,000 0.80

https://www.otcmarkets.com/file/company/financial-report/420983/content

FDA DECISION in August this could run to 50 cents even ahead of the decision and with approval it could hit 1 dollar

PharmaTher Announces FDA Extends Review Period for Ketamine; New Approval Goal Date August 9, 2025

$PHRRF PharmaTher is developing KETARX™ (ketamine) as part of its plans to support the Company’s commercialization initiatives and novel development programs for delivery KETARX™ (ketamine) in a patch and on-body pump for mental health, pain and medical countermeasures indications.
https://www.pharmather.com/ketarx-ketamine.html

Lets hope we get FDA approval.GLTA

$PHRRF March 2025 Corporate Presentation
https://www.pharmather.com/uploads/1/2/5/8/125844350/deck_-_phrm_-_1020201.pdf

Looking good ...

FDA has assigned a new goal date of approval for June 4th. I've waited a long time, what's another 80 or so days.

$PHRRF News March 3, 2025 - PharmaTher Provides Complete Response Amendment for US FDA New Drug Application for Ketamine https://www.pharmather.com/news/pharmather-provides-complete-response-amendment-for-us-fda-new-drug-application-for-ketamine